Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWERVAX Lung 1
2023-503221-19-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing LIBTAYO + BNT116 with LIBTAYO monotherapy (2 arms). Primary endpoint: Objective response rate. Planned start Apr 2024; status: authorised.
02
Drugs
cemiplimabBNT116
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503221-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503221-19-00.